202 related articles for article (PubMed ID: 32651571)
1. Simultaneous development of zanubrutinib in the USA and China.
Li G; Liu X; Chen X
Nat Rev Clin Oncol; 2020 Oct; 17(10):589-590. PubMed ID: 32651571
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
Weaver AN; Jimeno A
Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib approved for mantle cell lymphoma.
Cancer Discov; 2014 Jan; 4(1):OF1. PubMed ID: 24402946
[TBL] [Abstract][Full Text] [Related]
4. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
[TBL] [Abstract][Full Text] [Related]
5. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Bond DA; Maddocks KJ
Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
[TBL] [Abstract][Full Text] [Related]
6. Zanubrutinib: First Approval.
Syed YY
Drugs; 2020 Jan; 80(1):91-97. PubMed ID: 31933167
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib approved for the treatment of mantle cell lymphoma.
Small S
Clin Adv Hematol Oncol; 2013 Dec; 11(12):808. PubMed ID: 25016625
[No Abstract] [Full Text] [Related]
8. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.
Flinsenberg TWH; Tromedjo CC; Hu N; Liu Y; Guo Y; Thia KYT; Noori T; Song X; Aw Yeang HX; Tantalo DG; Handunnetti S; Seymour JF; Roberts AW; Ritchie D; Koldej R; Neeson PJ; Wang L; Trapani JA; Tam CS; Voskoboinik I
Haematologica; 2020; 105(2):e76-e79. PubMed ID: 31171645
[No Abstract] [Full Text] [Related]
9. Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.
Martynchyk A; Hawkes EA
Br J Haematol; 2024 May; 204(5):1582-1584. PubMed ID: 38581289
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
de Claro RA; McGinn KM; Verdun N; Lee SL; Chiu HJ; Saber H; Brower ME; Chang CJ; Pfuma E; Habtemariam B; Bullock J; Wang Y; Nie L; Chen XH; Lu DR; Al-Hakim A; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Aug; 21(16):3586-90. PubMed ID: 26275952
[TBL] [Abstract][Full Text] [Related]
11. Precision therapies take aim at non-Hodgkin's lymphoma.
Dolgin E
Nature; 2018 Nov; 563(7731):S46-S47. PubMed ID: 30429566
[No Abstract] [Full Text] [Related]
12. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Zhang L; Newberry KJ; Wang M
Expert Rev Clin Immunol; 2013 Jun; 9(6):495-7. PubMed ID: 23730878
[No Abstract] [Full Text] [Related]
13. Toward new treatments for mantle-cell lymphoma?
Zucca E; Bertoni F
N Engl J Med; 2013 Aug; 369(6):571-2. PubMed ID: 23924008
[No Abstract] [Full Text] [Related]
14. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
15. Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.
Morcos PN; Liu J; Blumenthal GM; Zhao H
Clin Pharmacol Ther; 2019 Apr; 105(4):826-828. PubMed ID: 30723888
[No Abstract] [Full Text] [Related]
16. [Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review].
Tang X; Zou WR; Peng P; Bai YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):965-969. PubMed ID: 35680835
[TBL] [Abstract][Full Text] [Related]
17. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials.
Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Zhou D; Tam CS; Simpson D; Wang M; Phillips TJ; Opat S; Huang Z; Lu H; Song Y; Song Y
J Hematol Oncol; 2021 Oct; 14(1):167. PubMed ID: 34649571
[TBL] [Abstract][Full Text] [Related]
18. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
[No Abstract] [Full Text] [Related]
19. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
20. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]